Diagnosis and treatment of primary myelodysplastic syndromes in adults: recommendations from the European LeukemiaNet
L Malcovati, E Hellström-Lindberg… - Blood, The Journal …, 2013 - ashpublications.org
Within the myelodysplastic syndrome (MDS) work package of the European LeukemiaNet,
an Expert Panel was selected according to the framework elements of the National Institutes …
an Expert Panel was selected according to the framework elements of the National Institutes …
Myelodysplasia
ML Heaney, DW Golde - New England Journal of Medicine, 1999 - Mass Medical Soc
The myelodysplastic syndromes are clonal hematologic disorders characterized clinically
and morphologically by ineffective hematopoiesis. The natural history of these syndromes …
and morphologically by ineffective hematopoiesis. The natural history of these syndromes …
Revised international prognostic scoring system for myelodysplastic syndromes
PL Greenberg, H Tuechler, J Schanz… - Blood, The Journal …, 2012 - ashpublications.org
Abstract The International Prognostic Scoring Sytem (IPSS) is an important standard for
ssessing prognosis of primary untreated adult patients with myelodysplastic syndromes …
ssessing prognosis of primary untreated adult patients with myelodysplastic syndromes …
International scoring system for evaluating prognosis in myelodysplastic syndromes
P Greenberg, C Cox, MM LeBeau… - Blood, The Journal …, 1997 - ashpublications.org
Despite multiple disparate prognostic risk analysis systems for evaluating clinical outcome
for patients with myelodysplastic syndrome (MDS), imprecision persists with such analyses …
for patients with myelodysplastic syndrome (MDS), imprecision persists with such analyses …
New comprehensive cytogenetic scoring system for primary myelodysplastic syndromes (MDS) and oligoblastic acute myeloid leukemia after MDS derived from an …
J Schanz, H Tüchler, F Solé, M Mallo, E Luno… - Journal of clinical …, 2012 - ascopubs.org
Purpose The karyotype is a strong independent prognostic factor in myelodysplastic
syndromes (MDS). Since the implementation of the International Prognostic Scoring System …
syndromes (MDS). Since the implementation of the International Prognostic Scoring System …
Time-dependent prognostic scoring system for predicting survival and leukemic evolution in myelodysplastic syndromes
L Malcovati, U Germing, A Kuendgen… - Journal of clinical …, 2007 - ascopubs.org
Purpose The aims of this study were to identify the most significant prognostic factors in
myelodysplastic syndromes (MDS) taking into account both their values at clinical onset and …
myelodysplastic syndromes (MDS) taking into account both their values at clinical onset and …
Prognostic factors and life expectancy in myelodysplastic syndromes classified according to WHO criteria: a basis for clinical decision making
L Malcovati, MGD Porta, C Pascutto… - Journal of Clinical …, 2005 - ascopubs.org
Purpose The aim of this study was to evaluate the prognostic value of the WHO proposal, to
assess the role of the main prognostic factors in myelodysplastic syndromes (MDSs) …
assess the role of the main prognostic factors in myelodysplastic syndromes (MDSs) …
A decision analysis of allogeneic bone marrow transplantation for the myelodysplastic syndromes: delayed transplantation for low-risk myelodysplasia is associated …
CS Cutler, SJ Lee, P Greenberg, HJ Deeg, WS Pérez… - Blood, 2004 - ashpublications.org
Bone marrow transplantation (BMT) can cure myelodysplastic syndrome (MDS), although
transplantation carries significant risks of morbidity and mortality. Because the optimal timing …
transplantation carries significant risks of morbidity and mortality. Because the optimal timing …
Role of reduced-intensity conditioning allogeneic hematopoietic stem-cell transplantation in older patients with de novo myelodysplastic syndromes: an international …
J Koreth, J Pidala, WS Perez, HJ Deeg… - Journal of clinical …, 2013 - ascopubs.org
Purpose Myelodysplastic syndromes (MDS) are clonal hematopoietic disorders that are
more common in patients aged≥ 60 years and are incurable with conventional therapies …
more common in patients aged≥ 60 years and are incurable with conventional therapies …
Myelodysplastic syndromes: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up†☆
P Fenaux, D Haase, V Santini, GF Sanz… - Annals of …, 2021 - annalsofoncology.org
Myelodysplastic syndromes (MDS) are clonal haematopoietic stem cell (HSC) disorders
predominating in the elderly, characterised by ineffective haematopoiesis leading to blood …
predominating in the elderly, characterised by ineffective haematopoiesis leading to blood …